Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36896 | 0.92 | LMNA (0.54) | LMNAALDH1A1POLBL3MBTL1TDP1 | |
| SCHEMBL21899454 | 0.88 | LMNA (0.51) | LMNAALDH1A1POLBL3MBTL1TDP1 | |
| SCHEMBL22946750 | 0.85 | LMNA (0.43) | LMNAALDH1A1POLBL3MBTL1TDP1 | |
| SCHEMBL1060074 | 0.85 | TAAR1 (0.55) | LMNAALDH1A1POLBL3MBTL1TDP1 | |
| SCHEMBL13399056 | 0.83 | LMNA (0.47) | LMNAALDH1A1POLBL3MBTL1TDP1 | |
| SCHEMBL11011561 | 0.82 | TDP1 (0.49) | LMNAALDH1A1POLBL3MBTL1TDP1 | |
| SCHEMBL9480396 | 0.81 | LMNA (0.45) | LMNAALDH1A1POLBL3MBTL1TDP1 | |
| SCHEMBL132721 | 0.81 | MEN1 (0.43) | LMNAALDH1A1POLBL3MBTL1TDP1 | |
| SCHEMBL20029979 | 0.80 | LMNA (0.45) | LMNAALDH1A1POLBL3MBTL1TDP1 | |
| SCHEMBL9866782 | 0.79 | ALDH1A1 (0.54) | LMNAALDH1A1POLBL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288264-B1 | Contact-killing antimicrobial devices | SURFACINE DEVELOPMENT COMPANY, L.L.C. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20060147549-A1 | Methods and compositions for reducing population of plant pathogen | ECOLAB USA INC. | 2006-07-06 | — | — | US | disclosed |
| US-6264936-B1 | CATIONIC POLYMER | BIOPOLYMERIX, INC. (GB) | 2001-07-24 | — | — | US | disclosed |
| US-6126931-A | COMBINATION OF AN ORGANIC MATRIX HAVING BIOCIDAL METALLIC MATERIALS NON-LEACHABLY ASSOCIATED WITH THE MATRIX. | SURFACINE DEVELOPMENT COMPANY, LLC (US) | 2000-10-03 | — | — | US | disclosed |
| US-5849311-A | Contact-killing non-leaching antimicrobial materials | BIOPOLYMERIX, INC. (GB) | 1998-12-15 | — | — | US | disclosed |
| US-5817325-A | IMMOBILIZED CATIONIC BIGUANIDE POLYMER MATRIX, METAL OR METAL COMPOUND | BIOPOLYMERIX, INC. (GB) | 1998-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060147549-A1 | Methods and compositions for reducing population of plant pathogen | IPMK, GMDS, PUF60 | LMNA 3654/4885ALDH1A1 3388/4885POLB 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.